Tian An Medicare (SEHK:383) Half Year Profit Tests Bullish Turnaround Narrative

Latest results set up a mixed picture for Tian An Medicare (SEHK:383)

Tian An Medicare (SEHK:383) has released its FY 2025 first half numbers, reporting revenue of HK$783.1 million and net income of HK$12.0 million, which translates to basic EPS of HK$0.011. Over the past three reported half year periods, the company has seen revenue move from HK$821.5 million in 1H 2024 to HK$805.7 million in 2H 2024 and HK$783.1 million in 1H 2025. Basic EPS tracked from HK$0.019943 to HK$0.00655 and then HK$0.011, giving investors a view of how earnings per share have shifted alongside a smaller top line. That mix of modest profit in the latest half against an unprofitable trailing twelve month profile focuses attention on how sustainable the current margin picture is.

See our full analysis for Tian An Medicare.

With the headline figures on the table, the next step is to weigh them against the prevailing market stories around Tian An Medicare and assess which narratives about growth, margins and profitability still hold up and which start to look stretched.

Curious how numbers become stories that shape markets? Explore Community Narratives

HK$11.98m profit against a loss over the last 12 months

• For 1H FY 2025 Tian An Medicare reported net income of HK$11.98m and basic EPS of HK$0.01105, while over the trailing 12 months the company recorded a net loss of HK$26.82m with basic EPS of HK$0.0248 loss.
• What stands out is how a profitable half year sits next to a loss over the last 12 months, which challenges a simple bullish view that the business has already turned the corner toward steady profitability.
  • Bulls pointing to the HK$11.98m profit in the latest half need to weigh it against the HK$26.82m loss across the trailing period.
  • The contrast between positive EPS of HK$0.017597 on a trailing basis at 1H 2025 and the later trailing EPS loss of HK$0.0248 shows that profit gains have not yet flowed through consistently.

Curious how these mixed profit and loss signals are shaping the bigger story for Tian An Medicare, and what other investors are focusing on beyond this single half year of results, 📊 Read the what the Community is saying about Tian An Medicare.

LTM loss shrinking 51.7% a year over five years

• Over the past five years the company has reduced its losses at an annualized rate of 51.7%, while still reporting a trailing 12 month net loss of HK$26.82m on HK$1.64b of revenue.
• Supporters of a bullish narrative often highlight that 51.7% annual loss reduction, and the latest half year profit of HK$11.98m, as signs of operational improvement, yet the current trailing loss shows that the journey toward sustained profitability is still in progress rather than complete.
  • The move from a trailing 12 month net income of HK$28.77m at 2H 2024 to a trailing loss of HK$26.82m at the latest point underlines how results can swing even as longer term loss ratios improve.
  • Revenue over the trailing 12 months sits at about HK$1.64b, which gives the loss reduction context but does not yet point to a stable earnings level that bullish investors can rely on.

HK$0.95 share price vs 0.6x P/S and HK$0.31 DCF fair value

• The shares trade at HK$0.95 with a P/S of 0.6x, below the Hong Kong Healthcare industry average of 0.9x, while a DCF fair value of HK$0.31 is well below the current price.
• Skeptics focus on the bearish angle that the stock trades above its DCF fair value while the company is still loss making over the last 12 months, and the numbers give that view some weight even as the lower P/S ratio offers a counterpoint.
  • A HK$0.95 price versus a DCF fair value estimate of HK$0.31 implies the market price is roughly 3x that modelled value, which bearish investors see as a valuation headwind alongside current losses.
  • At the same time a 0.6x P/S that is below the 0.9x industry average can appeal to investors who compare companies on sales multiples, so the data leaves room for both cautious and more optimistic interpretations.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Tian An Medicare's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

See What Else Is Out There

Tian An Medicare still pairs a trailing 12 month loss and uneven EPS with a share price that sits well above the stated DCF fair value.

If that mix of patchy profitability and valuation premium makes you cautious, check out 224 high quality undervalued stocks to focus on companies where pricing and fundamentals line up more tightly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com